Brian W Mccabe

US Patent:

20130116980, May 9, 2013

Filed:

Jul 2, 2012

Appl. No.:

13/539856

Inventors:

Nirod K. DAS - Ledgewood NJ, US
Brian McCabe - Orange CT, US

International Classification:

G06F 17/50

US Classification:

703 1

Abstract:

The problem of modeling and designing a structure including a planar element(s) (e.g., antenna, RF circuit, etc.) arranged in association with a non-planar element(s) (e.g., non-planar packaging, a non-planar scattering element, a complex meta material, a periodic array element, etc.), in a computationally efficient and rigorous manner is solved by (1) modeling each of the planar elements using both conventional space-spectral analysis and complex space-spectral analysis to obtain an electro-magnetic (EM) signature matrix for each planar element, (2) determining (e.g., using a brute force modeling based on Maxwell's equations, by measuring experimentally, or by reading one from a stored library) an EM signature matrix (e.g., reflection and scattering matrices) compatible with those of the planar elements, for each of the non-planar elements, and (3) combining the EM signatures of the elements using matrix analysis to obtain a complete EM signature the structure.

US Patent:

20150064234, Mar 5, 2015

Filed:

Mar 26, 2013

Appl. No.:

14/388421

Inventors:

Brian D. Mccabe - New York NY, US

Assignee:

THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - NEW YORK NY

International Classification:

A61K 31/4409
A61K 9/127

US Classification:

424450, 514352, 514357, 514605, 51425407, 514643, 514318, 514274, 514278

Abstract:

It has been discovered that pharmacological inhibition of K+ channels (using the FDA-approved broad-spectrum K+ channel antagonist 4-AP) positively benefitted smn mutant phenotypes, a result that is consistent with the defective excitability of motor circuits by their interneuron or sensory neuron inputs being a critical consequence of SMN depletion. Based on these observations, certain embodiments of the invention are directed to methods of treatment of SMA by administering therapeutically effective amounts of one or more potassium channel antagonists, including 4-aminopyridine, 4-(dimethylamino)pyridine, 4-(methylamino)pyridine, and 4-(aminomethyl)pyridine. Other embodiments are directed to new pharmaceutical formulations comprising two or more potassium channel antagonists.